Research Study: Randomized Open-Label Phase 3 Study of Single Agent Pembrolizumab versus Single Agent Chemotherapy per Physician’s Choice for Metastatic Triple Negative Breast Cancer (mTNBC)

Dr. Linda Vahdat is seeking women 18 years of age or older, diagnosed with metastatic triple negative breast cancer for a research study.

This clinical trial is for women with metastatic triple negative breast cancer (mTNBC). This means that the three most common types of receptors (estrogen, progesterone, and human epidermal growth factor [HER2]) known to fuel most breast cancer growth are not present in their cancer.

To learn more about the study and to see if you are eligible [go]

A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Two Prior Anti-HER2 Therapies and Require Systemic Treatment

Dr. Linda Vahdat is seeking men and women with HER2+ metastatic breast cancer to participate in a research study.

The purpose of this study is to evaluate the effectiveness of margetuximab in combination with standard of care chemotherapies in the setting of patients with metastatic HER2+ breast cancer who have received prior treatment with trastuzumab, pertuzumab, and adotrastuzumab.

To see learn more and see if you qualify to participate [go]

Copper depletion may reduce breast cancer relapse in patients at high risk

Dr. Linda Vahdat speaks with MDLinx about copper depletion research in triple negative breast cancer.

“Copper is an interesting element. It’s involved in multiple biologic processes, which are important for tumor progression both within the tumor itself and within the tumor microenvironment. In the tumor microenvironment, it facilitates tumors doing their bad things,” explained lead author Linda T. Vahdat, MD, MBA, professor of medicine, Weill Cornell Medicine and NewYork-Presbyterian, and director of the Breast Cancer Research Program and co-leader of the Breast Cancer Program, Meyer Cancer Center, New York, NY.

To learn more and see the original article and interview video [go]

Phase 1b/2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination with Pembrolizumab in Subjects With Metastatic Triple Negative Breast Cancer

Dr. Linda Vahdat is seeking volunteers for a new research study in triple negative breast cancer.

This clinical trial is for women with metastatic triple-negative breast cancer (mTNBC). This means that the three most common types of receptors (estrogen, progesterone, and human epidermal growth factor [HER2]) known to fuel most breast cancer growth are not present in their cancer.

The purpose of this study is to evaluate the effectiveness and safety of eribulin mesylate (“eribulin”) in combination with pembrolizumab in metastatic (spread of cancer from one part of body to another) triple-negative breast cancer.

For more information visit our website

You can also find us on Twitter and Facebook

Dr. Linda Vahdat on Gelmbatumumab Vedotin as a Treatment in Triple Negative Breast Cancer

“With antibody drug conjugates, generally speaking is that you can deliver a much higher dose of drug to the tumor than you normally would be able to. The hope is that if you can deliver the drug to the tumor that you can kill more cancer cells.” – Linda Vahdat, M.D. 
Linda Vahdat, MD, professor of Medicine, director of the Breast Cancer Research Program, chief of the Solid Tumor Service, Weill Cornell Medical, discusses the antibody drug conjugate glembatumumab vedotin being used in the treatment of women with triple negative breast cancer who have a high expression of gpNMB. Vahdat says the purpose of the drug conjugate is to target gpNMB, also known as osteoactivan, which is important for cell migration and invasion.

Vahdat says the hope among oncologists for glembatumumab vedotin is that the treatment can deliver a much higher dose of drug to the tumor than you normally would be able to, and directly into the tumor cell.

How cryotherapy prevents hair loss from chemo

For women getting chemotherapy to treat breast cancer, there’s a new device that could help them keep their hair.

Hair loss with chemotherapy is a hallmark side effect of the treatment. And until now, most women undergoing chemo had to accept it as part of the unavoidable price to pay for the potentially life-saving therapy.

But the Food and Drug Administration (FDA) just approved a new cooling cap that some women have already been using to prevent hair loss when being treated. The device, made by Swedish company Dignitana, has been available in Europe but is now approved for marketing in the U.S.

“Hair loss from chemo is probably ranked among the most dreaded side effects of chemotherapy,” says Dr. Tessa Cigler, assistant professor of medicine at the Weill Cornell Breast Center, which tested the cap on some of its patients. “I think this will make such a difference in so many women’s lives.”

The device, called DigniCap, has an inner layer that circulates very cooled liquid at 37 degrees F around the scalp; another layer essentially holds that cap in place and insulates the cold. The cold temperature chills the hair follicles, making the cells divide less frequently, and therefore making them less attractive as a target for the chemotherapy agent, which homes in on rapidly dividing cells like those in tumors. The cold also constricts blood vessels in the scalp, making it harder for the chemo drug to reach the hair follicles.

In a study that the FDA considered in its review, of 101 breast cancer patients at five centers in the U.S. who used the cold cap, the device prevented hair loss in 70% of the women. Without the cap, say doctors, the chemotherapy regimens the women received lead to hair loss in nearly 100% of cases.

Women don DigniCap about 30 minutes before starting their chemotherapy, wear it throughout the treatment and for another 30 to 60 minutes afterward.

The Weill Cornell Breast Center study involved women with early-stage breast cancer receiving the most common chemo regimens, so Cigler says that more studies are needed to see if it will work for other chemo combinations for other types of cancer and for later stage patients. Certain chemo regimens may simply be too harsh for the cryotherpy to work, for example.

Some doctors also raised the concern that for cancers that might spread to the brain, the chilling effect of the cap might prevent chemotherapy from working on stray cancer cells there. More studies will also reveal more about this potential danger as well.

In the meantime, the cap represents a huge improvement over the current cold cap technology, which involves rotating ice packs that have been frozen in dry ice, on the head every 30 minutes. Dignicap automates the cooling process and makes it less cumbersome for patients.

This article first appeared in TIME. Read the full story here.

Additional coverage on ABC News.

2015 Making Strides Against Breast Cancer Walk 10.18.15

American Cancer Society’s
2015 Making Strides Against Breast Cancer Walk
Join us as we help raise awareness & support to end breast cancer!
Sunday, October 18, 2015
Central Park, New York City
9:00AM
To Join our team or donate:
http://main.acsevents.org/site/TR?fr_id=69989&pg=team&team_id=1866227
Family & Friends are welcome to join!

Race Day:
8:15AM-Team Photo at Northwest corner of 72nd Street and Fifth Avenue

9:00AM–Walk

NewYork-Presbyterian team T-shirts will be available. Details to follow
For additional information: Christine Dillon chw9040@nyp.org

Weill Cornell Breast Center Conducting Free Genetic Testing for BRCA1 & BRCA2

The Weill Cornell Breast Center would like to invite all patients who meet the following criteria to contact us about free genetic testing for the BRCA1 and BRCA2 mutations:

  • Metastatic breast cancer
  • Her2neu negative breast cancer
  • No more than two prior regimens of chemotherapy in the metastatic setting

If you meet the criteria above, you may be eligible for free genetic testing. If you test positive for the gene mutation, you may be eligible to participate in one of our treatment trials.

Please contact Marta Cobham, RN at 212.821.0780 or mac2034@med.cornell.edu or Naomi Kornhauser, MPH at naw2007@med.cornell.edu for more information.

Awards & Honors

Dr. Eleni Andreopoulou, the Madeline and Stephen Anbinder Clinical Scholar in Hematology/Oncology and an assistant professor of clinical medicine, received the Archbishop Iakovos Leadership 100 Endowment Fund’s Award for Excellence on Feb. 14. One of the most prominent charitable Greek organizations in America, the group was founded in 1984 to bring together Greek Orthodox leaders across many fields and to support the work of other community members. Michael Jaharis, a member of the Weill Cornell Board of Overseers, is also a founding member of the fund.

Dr. Anne Moore, a professor in clinical medicine, has won the 2015 Virginia Kneeland Frantz Distinguished Women in Medicine Award from Columbia University College of Physicians and Surgeons. This award is presented annually to an alumna who has outstanding career achievements and is named in honor of Dr. Virginia Kneeland Frantz, one of the first six women allowed admission to the previously all-male college. After graduation in 1922, Dr. Krantz went on to become the first woman ever to be accepted into what was then named Presbyterian Hospital’s two-year surgical internship. Dr. Moore received the award during the college’s reunion event on May 8.

Congratulations to Drs. Andreopoulou & Moore for their continued efforts to treat women with breast cancer around the world.

Weill Cornell Physicians Selected for “Top Doctors 2015” List

Drs Vahdat, Moore, Simmons & Swistel named to Newsweek’s “Top Doctors 2015” list. The list is generated via interviewing physician peers.

“According to the NIH/National Cancer Institute, in 2015 an estimated 1,658,370 new cases of cancer will be diagnosed in the United States, and 589,430 people will die from the disease.

Newsweek, in conjunction with Castle Connolly Medical LTD, the well respected publisher of America’s Top Doctors®, is proud to present the list of the “Top Cancer Doctors 2015 ” for the United States.

This list was compiled through peer nominations and extensive research that Castle Connolly Medical LTD. has conducted for more than two decades.

The Castle Connolly physician-led research team makes tens of thousands of phone calls each year, talking with leading specialists, chairs of clinical departments and vice presidents of medical affairs, seeking to gather further information regarding the top specialists for most diseases and procedures. Each year, Castle Connolly receives nearly 100,000 nominations via this process. After a careful review of credentials, the following physicians have been selected to be a part of the Newsweek “Top Cancer Doctors 2015” list.”

To make an appointment at the Weill Cornell Breast Center please contact (212) 821-0644

Original publication http://www.newsweek.com/top-cancer-doctors-2015